What is claimed is:

1. An imaging agent composition comprisinges an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID. No 2~~-or a conservative variant thereof~~, conjugated with 18F-SiFA via an isotopic fluorine exchange chemistry wherein the isolated polypeptide binds specifically to HER2 or variants thereof.

2. A method of making an imaging agent composition according to claim 1 comprising (i) providing an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID No. 2~~-or a conservative variant thereof~~; (ii) reacting the polypeptide with a silicon fluoride-containing moiety to form a silicon fluoride conjugated polypeptide; and (iii) reacting the silicon fluoride conjugated polypeptide with an ^{18}F moiety or a source of ^{18}F to form an ^{18}F-silicon fluoride conjugated polypeptide.

3. A method of making an imaging agent composition according to claim 1 comprising (i) providing the isolated polypeptide comprising SEQ.ID No. 1, SEQ.ID No. 2~~, or a conservative variant thereof~~; (ii) reacting the polypeptide with a linker, wherein the linker comprises a SiFA group, to form a SiFA conjugated polypeptide; and (iii) reacting the SiFA conjugated polypeptide with an ^{18}F moiety or a source of ^{18}F.

4. A pharmaceutical composition comprising an imaging agent composition according to claim 1 and a pharmaceutically acceptable carrier.